Last checked at 
4 Apr 2022 07:00
London, UK, 4 April 2022
Edison issues review on The Biotech Growth Trust (BIOG)
The Biotech Growth Trust (BIOG) is managed by Geoff Hsu at healthcare specialist OrbiMed Capital, and benefits from OrbiMed's presence in 11 offices across the globe. While the trust has had a weak period of absolute and relative performance over the last 12 months, the manager believes that the focus on emerging biotech (smaller-cap) and emerging market biotech stocks is the correct strategy; following this approach proved very successful for BIOG's FY21 results. Investors are currently not focusing on the biotech sector's strong fundamentals, and the sell-off since early-February 2021 may have created a very attractive entry point for those willing to look beyond the current cyclical/value stock market leadership.
Perhaps reflecting weakness in the biotech sector, BIOG's valuation has been volatile since the middle of 2021. Its current 6.6% discount to cum-income NAV compares with a range of a 3.3% premium to an 11.5% discount over the last 12 months. Over the last one, three, five and 10 years the trust's average discounts are 2.5%, 4.3%, 5.0% and 4.6%, respectively.
Click here to view the full report or here to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website
www.edisongroup.com
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com
Sarah Godfrey +44 (0)20 3077 5700 investmenttrusts@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv